American Regent launches sulphite-free Epinephrine Injection
31 March 2023 -

American Regent, a subsidiary of New York-based Luitpold Pharmaceuticals, Inc., announced on Thursday that it has introduced its sulphite-free Epinephrine Injection, USP.

Epinephrine Injection, USP, is indicated for emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from insect stings or bites, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Epinephrine is also indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock, and is supplied as a 1 mg/mL 1 mL ampule in a shelf pack of 10.

Joann Gioia, vice president and chief commercial officer at American Regent, Inc, said, 'With the approval of this generic alternative, we continue to show our commitment to ensuring both patients and providers have access to quality treatment options.'